A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of MK-7240 in Participants with Moderately to Severely Active Ulcerative Colitis
Primary Objective
To evaluate the efficacy of MK-7240 compared to Placebo as assessed by the proportion of participants achieving clinical remission per Modified Mayo Score at Week 12
Description
A phase three study to evaluate the safety and tolerability of MK-7240 for patients who have moderate to severely active ulcerative colitis (UC).
Details
Age
Adult
Eligibility
UC as defined by Modified May Score of 5-9, Endoscopic sub-score greater than or equal to 2Has inadequate response or LOR to 1 more prior UC therapy.
Locations
Outpatient CTRC
University of Colorado Hospital
Principal Investigator
Mark Gerich
Study ID
Protocol Number: 23-2563
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers